Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of its Rapid Sepsis Solution• In the first 12 months on market, the ~8-minute FDA-cleared IntelliSep test has helped hospitals save lives and money while delivering patient-centered care

Cytovale完成了1亿美元的D系列资金，以加速其快速败血症解决方案的商业扩张•在上市的前12个月，约8分钟的FDA批准的IntelliSep测试帮助医院挽救了生命和金钱，同时提供了以患者为中心的护理

• These real world outcomes attracted investors to help accelerate commercialization and arm emergency departments across the U.S. with this early sepsis detection technologySAN FRANCISCO, October 10, 2024-- Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $100 million in Series D funding led by Sands Capital.

•这些现实世界的成果吸引了投资者，帮助加速美国各地的商业化和武装急诊部门。凭借这种早期脓毒症检测技术，旧金山，2024年10月10日——Cytovale®，一家商业阶段的医疗诊断公司，专注于推进早期检测技术，以诊断快速发展和免疫介导的疾病，今天宣布它已经在金沙资本（Sands Capital）领导的D系列融资中筹集了1亿美元。

The round included participation from new investor Canada Pension Plan Investment Board (CPP Investments), as well as existing investors Norwest Venture Partners, Global Health Investment Corporation and Breakout Ventures, an early backer of the company. Cytovale will use the funding to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments (ED) and health systems nationwide..

新投资者加拿大养老金计划投资委员会（CPP Investments）以及现有投资者Norwest Venture Partners、全球健康投资公司（Global Health Investment Corporation）和Breakout Ventures（该公司的早期支持者）参与了这轮投资。Cytovale将利用这笔资金在其早期临床成功的基础上再接再厉，并加速IntelliSep向全国更多医院急诊科（ED）和卫生系统的商业扩张。。

'Sepsis is the largest single condition presenting to the Emergency Department where there hasn't been an effective diagnostic to quickly and effectively triage patients. Cytovale's IntelliSep test has now been demonstrated, prospectively, to help save lives and money by doing just that,' said Parker Cassidy, partner, Sands Capital.

“脓毒症是急诊科面临的最大的单一病症，目前还没有有效的诊断方法来快速有效地对患者进行分类。金沙资本（SandsCapital）合伙人帕克·卡西迪（ParkerCassidy）说，Cytovale的IntelliSep测试已经被证明可以通过这样做来帮助挽救生命和金钱。

'We're excited to lead this financing and help accelerate Cytovale's commercial launch.'.

“我们很高兴能够领导此次融资，并帮助加速Cytovale的商业启动。”。

IntelliSep is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in the ED, where over 80% of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care..

IntelliSep是美国食品和药物管理局（FDA）批准的第一个也是唯一一个用于ED的细胞宿主诊断，其中超过80%的败血症病例存在。这项测试只需要大约八分钟，为临床医生提供了有史以来第一次研究导致败血症的生物学，使护理团队能够快速而自信地确定正确的诊断并提供适当的以患者为中心的护理。。

'Seeing sepsis is a major breakthrough; IntelliSep allows our care teams in the Emergency Department to quickly and accurately triage and diagnose suspected infection patients and put them on the right path for treatment,' said Dr. Christopher Thomas, chief quality officer, Franciscan Missionaries of Our Lady Health System.

“看到败血症是一个重大突破；“IntelliSep使我们急诊科的护理团队能够快速准确地对疑似感染患者进行分类和诊断，并将他们置于正确的治疗路径上，”圣母玛利亚卫生系统方济各会传教士首席质量官克里斯托弗·托马斯博士说。

'The meaningful clinical, operational and financial benefits we have experienced have led us to implement IntelliSep across all major hospitals in our health system.'.

“我们所经历的有意义的临床，运营和财务效益使我们在卫生系统的所有主要医院实施了IntelliSep。”。

IntelliSep launched in August 2023 at Our Lady of the Lake Regional Medical Center in Baton Rouge, La. The hospital has reported that, as a result of an IntelliSep-driven screening process, patients with occult sepsis were detected earlier and had treatment initiated more than 60 minutes faster. The hospital also saw a 30% decrease in the risk-adjusted mortality index for sepsis patients.

IntelliSep于2023年8月在路易斯安那州巴吞鲁日的圣母湖地区医疗中心推出。该医院报告说，由于IntelliSep驱动的筛查过程，隐匿性败血症患者被发现得更早，治疗开始的速度快了60分钟以上。该医院还发现脓毒症患者的风险调整死亡率指数下降了30%。

From an operational and financial perspective, patients tested with IntelliSep spent 1.28 fewer days in the hospital, and realized a savings of $1,400 per patient..

从运营和财务角度来看，接受IntelliSep测试的患者住院天数减少了1.28天，每位患者节省了1400美元。。

'Sepsis has historically been one of the most challenging and costly conditions for hospitals to manage due to the lack of rapid, objective diagnostic tools. Thankfully, that's finally changing with IntelliSep, which holds the potential to transform sepsis care in the same way troponin tests did for cardiac care and rapid CT scans did for stroke diagnosis,' said Cytovale CEO Ajay Shah, PhD.

“由于缺乏快速，客观的诊断工具，脓毒症一直是医院管理最具挑战性和成本最高的疾病之一。值得庆幸的是，IntelliSep终于改变了这种情况，它有可能改变脓毒症护理，就像肌钙蛋白检测用于心脏护理和快速CT扫描用于中风诊断一样，”Cytovale首席执行官Ajay Shah博士说。

'Cytovale is growing at an astounding pace to meet demand from other health systems looking to tackle this deadly condition. The additional investment will enable us to quickly scale across the U.S. with greater agility to serve health systems and their patients.'.

“Cytovale正在以惊人的速度增长，以满足其他卫生系统寻求解决这种致命疾病的需求。额外的投资将使我们能够以更大的灵活性在美国快速扩展，为卫生系统及其患者提供服务。”。

About Cytovale®

关于Cytovale®

Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep®, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis.

Cytovale致力于通过开创早期检测技术来改善患者护理，该技术可评估免疫激活，以加速从分诊到挽救生命的治疗所需的时间。Cytovale的美国食品和药物管理局（U.s.Food and Drug Administration）批准了快速脓毒症诊断IntelliSep®，它利用机器学习和先进的微流体技术，为急诊科临床医生提供客观且高度敏感的脓毒症早期检测工具。

IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital, Global Health Investment Corporation (GHIC), CPP Investments, Breakout Ventures and other leading investors.

IntelliSep测量免疫系统对感染的失调反应，这表明败血症，并使用标准抽血在大约八分钟内产生结果。Cytovale总部位于旧金山，由Norwest venture Partners、Sands Capital、Global Health Investment Corporation（GHIC）、CPP Investments、Breakout Ventures和其他领先投资者支持。

For more information, visit www.cytovale.com and follow Cytovale on LinkedIn and X..

有关更多信息，请访问www.cytovale.com，并在LinkedIn和X上关注cytovale。。